Houston, TX - November 17, 2010 – Capital Royalty L.P. (“Capital Royalty”) announced today that it has established a Strategic Advisory Committee (“SAC”) comprised of world-class leaders with extensive experience in building global biopharmaceutical companies, managing large scale research and development initiatives, and developing national healthcare policies. Capital Royalty’s SAC was created to support the firm’s investment team in identifying emerging industry trends, broadening industry relationships around the globe, and evaluating new investment opportunities.
Sidney Taurel, a Senior Advisor at Capital Royalty, is Chairman of the SAC and responsible for leading and directing the activities of the SAC. Mr. Taurel is joined on the SAC by Dr. Mark McClellan, Henri Termeer, and Dr. Tadataka “Tachi” Yamada.
· Sidney Taurel, Senior Advisor and Chairman of the SAC, is Chairman emeritus of Eli Lilly and Company. Mr. Taurel joined Eli Lilly and Company in 1971 and worked at the company for 37 years, 15 of which were spent on international assignments based in Sao Paulo, Vienna, Paris, and London. Mr. Taurel held senior leadership positions for 23 years, becoming President of Lilly International in 1986, President of the Pharmaceutical Division in 1993, COO in 1996, CEO in 1998, and Chairman of the Board in 1999. He retired as Chairman and CEO in 2008. Mr. Taurel was integral in shaping Lilly’s long-term future direction, including a strategic focus in building product pipelines through partnerships and licensing activities, many of which created large royalty streams. Over his career, Mr. Taurel completed over $30 billion in acquisitions and licensing transactions.
· Dr. Mark McClellan (M.D. and Ph.D.), member of the SAC, is a highly distinguished medical doctor and economist, who works on promoting high-quality, innovative, and affordable healthcare. Dr. McClellan is a former Commissioner of the FDA and Administrator of the Centers for Medicare & Medicaid Services (“CMS”). As the Administrator of the CMS, he oversaw programs serving more than 80 million Americans at a cost of about $570 billion annually. Dr. McClellan has helped develop several key reforms to healthcare policy, including the Medicare Prescription Drug Benefit, changes to the State Children's Health Insurance Program, and public-private initiatives to obtain information on the quality and cost of healthcare. He also championed the FDA’s Critical Path initiative, which recognizes the need for collective action to modernize scientific and technical tools as well as information technology to evaluate and predict the safety, effectiveness, and manufacturability of medical products. Dr. McClellan is currently Director of the Engelberg Center for Health Care Reform and Leonard D. Schaeffer Chair of Health Policy Studies at the Brookings Institution.
· Henri A. Termeer, member of the SAC, was appointed President of Genzyme Corporation in 1983, two years after the company's founding. He became its CEO in 1985 and Chairman in 1988. Under his leadership, Genzyme Corporation has grown to become one of the world's leading biotechnology companies. Widely acknowledged for his contributions to the biotechnology industry and healthcare field, Mr. Termeer is active in the areas of humanitarian assistance, policy issues, and innovation in providing access to health care. Mr. Termeer is Chairman of the Federal Reserve Bank of Boston's board of directors. He serves on the board of directors of the Pharmaceutical Research and Manufacturers of America. He is a director of Massachusetts General Hospital, a Board member of Partners HealthCare and a member of the Board of fellows of Harvard Medical School.
· Dr. Tachi Yamada (M.D.), member of the SAC, is President of the Bill and Melinda Gates Foundation’s Global Health Program. In this capacity, he leads the Global Health Program’s efforts to help develop and deliver low-cost, life-saving healthcare tools for the developing world. Prior to joining the Global Health Program, Dr. Yamada was Chairman of Research and Development at GlaxoSmithKline and a member of the company’s Board of Directors. During his tenure at GlaxoSmithKline, Dr. Yamada oversaw more than 100 clinical projects, managed an annual budget exceeding $4 billion, and directed more than 15,000 employees based throughout the world. He has been credited with transforming research and development efforts at GlaxoSmithKline, and significantly expanding the company’s product pipeline. Prior to GlaxoSmithKline, he was Chairman of the Department of Internal Medicine at the University of Michigan Medical School and Physician-in-Chief at the University of Michigan Medical Center.
“It is rare to find a group of such highly accomplished leaders in one organization. Capital Royalty’s recent success and innovative approach to healthcare investing have helped us attract a Strategic Advisory Committee that brings together some of the most experienced executives and policy makers in the healthcare industry.” said Sidney Taurel, Capital Royalty Senior Advisor and Chairman of the SAC.
“We expect to benefit from the SAC’s unique market perspectives and unparalleled access to other industry leaders around the world. The formation of our Strategic Advisory Committee is another step in positioning Capital Royalty for continued success in healthcare investing.” said Charles W. Tate, Capital Royalty Founder and Chairman.
ABOUT CAPITAL ROYALTY L.P.
Founded in 2003, Capital Royalty L.P. is a market pioneer and innovator in healthcare investing with a focus on intellectual property investments in FDA-approved biopharmaceutical assets. Collectively, the Capital Royalty investment team has more than 140 years of healthcare, capital markets, private equity and investment banking experience, having completed more than 50 royalty transactions representing $3.7 billion in capital over the past fifteen years. Capital Royalty focuses on sourcing, structuring and investing in healthcare royalty monetization transactions that target attractive risk-adjusted returns with superior downside protection for investors. The Firm is headquartered in Houston, Texas with offices in New York, New York and Boulder, Colorado. For further information, please visitwww.capitalroyalty.com.